Platform Simplifies IoT Learning with Teacher Management System, Multi-Data Monitoring, and Enhanced User Experience. Our ...

ATLANTA, GA- June 10, 2025- GeoVax Labs, Inc., a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and solid tumors, today ...

Arm Holdings continues to deliver strong revenue growth and impressive margin expansion. But read why I'm downgrading ARM stock to Hold.

In this post-hoc analysis, data were pooled from the randomised, placebo-controlled, phase 3 TULIP-1 (NCT02446912) and TULIP-2 (NCT02446899) trials of anifrolumab (300 mg intravenously once every 4 ...

Among the patients with PD-L1 TPS<1%, IBI363 demonstrated outstanding efficacy signals: in the 1/1.5 mg/kg group (N=10), the confirmed ORR was 30.0% and the DCR was 90.0%, while that of the 3 mg/kg ...

PD-1/IL-2 α-bias bispecific antibody fusion protein IBI363 in patients with immunotherapy resistant advanced non-small cell lung cancer: results from a Phase 1 study. Updated data on IBI363 ...

As of March 14, 2025, a total of 83 patients with pancreatic cancer had received at least one dose of IBI343 with a median follow-up time of 11.1 months. As the data cutoff date, in patients with ...

Late-breaking oral presentation will highlight new data from a trial of INCA033989, an anti-mutant calreticulin (mutCALR)-directed monoclonal antibody, in patients with essential thrombocythemia (ET) ...

IBM on Monday said that it has acquired Seek AI, an AI platform that allows users to ask questions about enterprise data using natural language, for an undisclosed sum.. Seek CEO and founder Sarah ...

IBM on Monday said that it has acquired Seek AI, an AI platform that allows users to ask questions about enterprise data using natural language, for an undisclosed sum. Seek CEO and founder Sarah ...

A Phase 1/2 clinical study of PD-1/IL-2 α-bia s bispecific antibody fusion protein (IBI363) in the treatment of advanced "cold" tumor subtypes (acral and mucosal) malignant melanoma. The data ...

The analysis excluding qualifying variant carriers of telomere variants, as they are expected to have worse survival, revealed an increased but still non-significant effect for non-telomere variants ...